Innoveren Scientific (IVRN) 10-Q 4 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 03, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-36763
Entity Registrant Name	H-CYTE, INC
Entity Central Index Key	0001591165
Entity Tax Identification Number	46-3312262
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2202 N. West Shore Blvd
Entity Address, Address Line Two	Ste 200
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33607
City Area Code	(844)
Local Phone Number	633-6839
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HCYT
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		255,087,503

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current Assets
Cash	$ 341,284	$ 95,172
Accounts receivable	7,238	13,500
Patient financing receivable, current portion	55,200	43,900
Other receivables	3,831
Prepaid expenses	170,464	44,884
Total Current Assets	578,017	197,456
Property and equipment, net	35,196	38,374
Patient financing receivable, net of current portion	69,619	67,163
Other assets	18,413	18,412
Total assets	701,245	321,405
Current Liabilities
Accounts payable	680,204	585,291
Accrued liabilities	150,253	164,680
Other current liabilities	139,570	28,246
Notes payable, current portion	69,455	69,455
Convertible notes payable, related parties	1,969,174	1,969,174
Convertible notes payable	1,355,826	1,355,826
PPP Loan, current portion	26,536	66,275
Deferred revenue	60,927	414,025
Lease liability, current portion	97,066	94,805
Interest payable, related parties	137,993	98,055
Interest payable	109,453	75,048
Total Current Liabilities	4,796,457	4,920,880
Long-term Liabilities
Lease liability, net of current portion	37,753	62,768
Total Long-term Liabilities	37,753	62,768
Total Liabilities	4,834,210	4,983,648
Stockholders’ Equity (Deficit)
Preferred Stock - $.001 par value:  1,000,000,000 shares authorized; Series A Preferred Stock - $.001 par value: 800,000,000 shares authorized, 498,229,804 and 501,887,534 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively.	498,229	501,887
Common stock - $.001 par value: 1,600,000,000 shares authorized, 251,436,818 and 164,199,792 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively.	251,437	164,199
Additional paid-in capital	48,037,565	43,700,084
Accumulated deficit	(52,920,196)	(49,028,413)
Total Stockholders’ Deficit	(4,132,965)	(4,662,243)
Total Liabilities and Stockholders’ Deficit	$ 701,245	$ 321,405

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,600,000,000	1,600,000,000
Common stock, shares issued	251,436,818	164,199,792
Common stock, shares outstanding	251,436,818	164,199,792
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	800,000,000	800,000,000
Preferred stock, shares issued	498,229,804	501,887,534
Preferred stock, shares outstanding	498,229,804	501,887,534

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenues	$ 379,560	$ 376,168
Cost of Sales	(86,505)	(198,649)
Gross Profit	293,055	177,519
Operating Expenses
Salaries and related costs	347,219	661,775
Share based compensation	226,079
Other general and administrative	509,911	918,912
Total Operating Expenses	1,083,209	1,580,687
Operating Loss	(790,154)	(1,403,168)
Other Income (Expense)
Inducement Expense	(3,024,872)	(5,784)
Interest Expense	(72,352)
Other (expense) income	(4,405)	1,278
Total Other Expense	(3,101,629)	(4,506)
Net Loss	(3,891,783)	(1,407,674)
Net Loss attributable to common stockholders	$ (3,891,783)	$ (1,407,674)
Loss per share - basic and diluted	$ (0.02)	$ (0.01)
Weighted average outstanding shares - basic and diluted	169,154,701	128,283,919

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance at Dec. 31, 2020	$ 538,109	$ 127,159	$ 42,515,999	$ (44,229,106)	$ (1,047,839)
Beginning balance, shares at Dec. 31, 2020	538,109,409	127,159,464
Conversion of Series A Preferred Stock to Common Stock	$ (9,680)	$ 9,680
Conversion of Series A Preferred Stock to Common Stock, shares	(9,679,834)	9,679,834
Net loss				(1,407,674)	(1,407,674)
Ending balance at Mar. 31, 2021	$ 528,429	$ 136,839	42,515,999	(45,636,780)	(2,455,513)
Ending balance, shares at Mar. 31, 2021	528,429,575	136,839,298
Beginning balance at Dec. 31, 2021	$ 501,887	$ 164,199	43,700,084	(49,028,413)	(4,662,243)
Beginning balance, shares at Dec. 31, 2021	501,887,534	164,199,792
Conversion of Series A Preferred Stock to Common Stock	$ (3,658)	$ 3,658
Conversion of Series A Preferred Stock to Common Stock, shares	(3,657,730)	3,657,730
Inducement expense			3,024,872		3,024,872
Conversion of warrants to Common Stock		$ 83,580	1,086,530		1,170,110
Conversion of warrants to Common Stock, shares		83,579,296
Share based compensation			226,079		226,079
Net loss				(3,891,783)	(3,891,783)
Ending balance at Mar. 31, 2022	$ 498,229	$ 251,437	$ 48,037,565	$ (52,920,196)	$ (4,132,965)
Ending balance, shares at Mar. 31, 2022	498,229,804	251,436,818

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash Flows from Operating Activities
Net loss	$ (3,891,783)	$ (1,407,674)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,177	11,571
Share based compensation expense	226,079
Inducement expense	3,024,872
Changes in operating assets and liabilities:
Accounts receivable	6,262	(40,500)
Patient financing receivable, current portion	(11,300)
Other receivables	(3,831)	20,986
Prepaid expenses and other assets	(148,334)	(115,026)
Patient financing receivable, net of current portion	(2,456)
Accounts payable	94,913	142,629
Accrued liabilities	(14,427)	(39,638)
Other current liabilities	111,324	169,789
Deferred revenue	(353,098)	(52,890)
Interest payable, related parties	39,937
Interest payable	34,406	3,940
Net Cash Used in Operating Activities	(884,259)	(1,306,813)
Cash Flows from Investing Activities
Purchase of property and equipment		(1,522)
Net Cash Used in Investing Activities		(1,522)
Cash Flows from Financing Activities
Proceeds from warrant exercise related to inducement	1,170,110
Payment on PPP Loan	(39,739)
Net Cash Provided by Financing Activities	1,130,371
Net Change in Cash	246,112	(1,308,335)
Cash – Beginning of period	95,172	1,640,645
Cash – End of period	341,284	332,310
Supplementary Cash Flow Information
Cash paid for interest	1,378	1,844
Non-cash financing activities
Conversion of Series A Preferred Stock to Common Stock	3,658	9,680
Issuance of warrants pursuant to inducement agreements	2,993,872
Issuance of warrants for services rendered	$ 31,000

DESCRIPTION OF THE COMPANY

DESCRIPTION OF THE COMPANY	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
DESCRIPTION OF THE COMPANY	Note 1 - Description of the Company DESCRIPTION OF THE COMPANY H-CYTE, Inc (“the Company”) is a hybrid-biopharmaceutical company dedicated primarily to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. During the last three years, the Company has evolved into two separate divisions with its entrance into the biologics and device development space (“Biotech Division”). This division is complementary to the Company’s current Lung Health Institute (LHI) autologous infusion therapy business (“Infusion Division”) and is focused on underserved disease states. On September 8, 2021, the Company announced that its Lung Health Institute facilities changed their names to Centers for Respiratory Health as the clinics continue to deliver treatments for patients with chronic respiratory and pulmonary disorders. The consolidated results for H-CYTE include the following wholly-owned subsidiaries: H-CYTE Management, LLC, Medovex Corp, Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC and the results include Lung Institute Dallas, LLC (“LI Dallas”), Lung Institute Nashville, LLC (“LI Nashville”), Lung Institute Pittsburgh, LLC (“LI Pittsburgh”), and Lung Institute Scottsdale, LLC (“LI Scottsdale”), as Variable Interest Entities (“VIEs”). Additionally, H-CYTE Management, LLC is the operator and manager of the various Lung Health Institute (LHI) clinics: LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale. The LI Dallas and LI Pittsburgh clinics did not reopen in 2020 after the temporary closure of all LI clinics due to COVID-19. These two clinics will remain permanently closed. During the first quarter of 2022, the Company decided to close the LI Tampa and LI Nashville clinics. The LI Scottsdale clinic will remain open. Impact of COVID-19 The coronavirus outbreak (“COVID-19”) has adversely affected the Company’s financial condition and results of operations. The impact of the COVID-19 outbreak on businesses and the economy in the United States is expected to continue to be significant. The extent to which the COVID-19 outbreak will continue to impact businesses and the economy is highly uncertain. Accordingly, the Company cannot predict the extent to which its financial condition and results of operation will be affected. On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency caused by a new strain of the coronavirus and advised of the risks to the international community as the virus spread globally. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic based on the rapid increase in exposure globally. The spread of COVID-19 coronavirus has caused public health officials to recommend precautions to mitigate the spread of the virus, especially as to travel and congregating in large numbers. In addition, certain states and municipalities have enacted quarantining regulations which severely limit the ability of people to move and travel. In addition, the Company is uncertain of the full effect the pandemic will have on it for the longer term since the scope and duration of the pandemic is unknown, and evolving factors such as the level and timing of the distribution of efficacious vaccines across the world and the extent of any resurgences of the virus or emergence of new variants of the virus, such as the Delta variant and the Omicron variant, will impact the stability of economic recovery and growth. The Company may experience long-term disruptions to its operations resulting from changes in government policy or guidance; quarantines of employees, customers and suppliers in areas affected by the pandemic; and closures of businesses or manufacturing facilities critical to its business. Autologous Infusion Therapy (“Infusion Division”) The Company’s Infusion Division develops and implements innovative treatment options in autologous cellular therapy (PRP-PBMC) to treat chronic lung disorders. Committed to an individualized patient-centric approach, this division consistently provides oversight and management of the highest quality care to the LHI clinics located in Tampa, Nashville, and Scottsdale, while producing positive medical outcomes following the strictest CDC guidelines. During the first quarter of 2022, the Company decided to close the clinics in Tampa and Nashville, the Scottsdale clinic will remain open. Biotech Development (“Biotech Division”) During the year ended December 31, 2021, the Company completed a review of the R&D status regarding the exclusive product supply and services agreements with Rion, LLC (“Rion”) to develop and distribute (post U.S. Food & Drug Administration, the “FDA”, approval) a biologic combining its PRP-PBMC (“PRP”) technology with Rion’s exosomes (“EV”) technology for the treatment of chronic obstructive pulmonary disease (“COPD”). The Company has determined a single entity biologic from an alternative commercial source will be a more viable solution. The Company has decided to move away from Rion’s PRP technology and is progressing alternate biologics and therapeutic devices to meet the needs of the business.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
BASIS OF PRESENTATION	Note 2 – Basis of presentation BASIS OF PRESENTATION The accompanying interim consolidated financial statements have been prepared based upon U.S. Securities and Exchange Commission rules that permit reduced disclosure for interim periods. Therefore, they do not include all information and footnote disclosures necessary for a complete presentation of the Company’s financial position, results of operations and cash flows, in conformity with generally accepted accounting principles. The Company filed audited consolidated financial statements as of and for the fiscal years ended December 31, 2021 and 2020, which included all information and notes necessary for such complete presentation in conjunction with its 2021 Annual Report on Form 10-K. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. The results of operations for the interim period ended March 31, 2022 are not necessarily indicative of the results to be expected for any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021, which are contained in the Company’s 2021 Annual Report on Form 10-K. For further discussion refer to Note 2 – “Basis Of Presentation And Summary of Significant Accounting Policies” to the consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

LIQUIDITY, GOING CONCERN AND MA

LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS	Note 3 - Liquidity, Going Concern and Management’s Plans LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS The Company incurred net losses of approximately $ 3,892,000 1,408,000 COVID-19 has adversely affected the Company’s financial condition and results of operations. The impact of the outbreak of COVID-19 on the economy in the U.S. and the rest of the world is expected to continue to be significant. The extent to which the COVID-19 outbreak will continue to impact the economy is highly uncertain and cannot be predicted. Accordingly, the Company cannot predict the extent to which its financial condition and results of operations will be affected. The Company had cash on hand of approximately $ 341,000 as of March 31, 2022 and approximately $ 92,000 There can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings will be workable or acceptable to the Company or its shareholders. If the Company is unable to fund its operations from existing cash on hand, operating cash flows, additional borrowings, or raising equity capital, the Company may be forced to discontinue operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. In January 2022, the Company offered certain warrant holders the opportunity to receive an additional warrant to purchase the Company’s Common Stock at $ 0.014 per share, for a period of five ( 5 ) years from issuance for the exercise of each existing warrant originally issued in April 2020 prior to March 31, 2021. As of March 31, 2022, the Company had eleven warrant holders exercise an aggregate of 83,579,296 warrants at $ 0.014 per share resulting in cash proceeds of approximately $ 1,170,000 to the Company. The Company filed a Registration Statement on Form S-1 registering the resale of the shares of common stock issuable upon exercise of the warrants issued in the April 2020 financing. The registration statement was declared effective on February 14, 2022

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	Note 4 – Related Party Transactions RELATED PARTY TRANSACTIONS Officers and Board Members and Related Expenses On January 12, 2021, Mr. Raymond Monteleone was appointed as Chairman of the Board, Audit Committee Chair, and Compensation Committee Chair. There are understandings between the Company and Mr. Monteleone for him to receive $ 5,000 2,500 7,500 2,500 25,000 17,500 Mr. Michael Yurkowsky entered into an oral agreement with the Company on October 1, 2020, in which Mr. Yurkowsky will receive $ 4,167 0 12,500 Upon Mr. Yurkowsky’s appointment as CEO in December 2021, the Company terminated his payments for serving on the Board of Directors. On January 12, 2021, Mr. William Horne stepped down as Chairman of the Board. Mr. Horne will remain a member of the Board. Effective March 1, 2021, the Company entered into an oral agreement with Mr. Horne in which Mr. Horne will receive $ 4,167 per month to serve on the Board of Directors. Mr. Horne agreed to continue to defer the $ 108,000 in base salary deferred by him in 2018 until such time as there is a positive cash flow to meet the Company’s financial obligations and then the Company and Mr. Horne will work together in good faith to negotiate a payment plan for such deferred salary. Effective December 1, 2021, Mr. Horne will receive $ 5,000 per month to serve on the Board of Directors. For the three months ended March 31, 2022 and 2021, the Company expensed approximately $ 20,000 and $ 4,000 , respectively, in compensation and board of director fees to Mr. Horne. Mr. Richard Rosenblum entered into an oral agreement with the Company effective January 17, 2022, in which Mr. Rosenblum will receive $ 5,000 12,500 0 Mr. Matthew Anderer entered into an oral agreement with the Company effective January 17, 2022, in which Mr. Anderer will receive $ 5,000 12,500 0 Debt and Other Obligations Convertible Notes Payable On April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase Agreement”) with five (5) investors (the “Holders”). Pursuant to the terms of the April 2021 Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $ 2,575,000 March 31, 2022 8 20 1,500,000 25,000 On October 14, 2021, the Company entered into the Second Closing Bring Down Agreement (the “October 2021 Note Purchase Agreement”) whereby the five (5) investors who had entered into the April 2021 Note Purchase Agreement purchased new notes in the Company in the aggregate principal amount of $ 750,000 . The Notes are due and payable on March 31, 2022 and bear interest at an annual rate of 8 %. The Notes are convertible into shares of Common Stock at a discount of 20 % to the price paid for such New Securities in the next financing that meets the definition of a Qualified Financing as defined in the Note Purchase Agreement. The Notes are secured by all of the assets of the Company under a security agreement with the Holders. The lead investor of the October 2021 Note Purchase Agreement, FWHC Bridge, LLC, advanced $ 437,000 of the total amount to the Company. FWHC Bridge, LLC is an affiliated entity of FWHC, LLC, which is a principal stockholder and related party of the Company. An additional affiliate of FWHC, LLC provided an additional $ 7,000 as part of the October 2021 Note Purchase Agreement. Management is currently working with the noteholders on the extension of the maturity of the outstanding notes. The Company chose to early adopt effective January 1, 2021, ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contract in Entity’s Own Equity. Thus, the April 2021 and October 2021 Note Purchase Agreements did not require consideration of a beneficial conversion feature and were accounted for solely as debt on the balance sheets.

EQUITY TRANSACTIONS

EQUITY TRANSACTIONS	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
EQUITY TRANSACTIONS	Note 5 - Equity Transactions EQUITY TRANSACTIONS In January 2022, the Company offered certain warrant holders the opportunity to receive an additional warrant to purchase the Company’s Common Stock at $ 0.014 5 83,579,296 0.014 1,170,000 Series A Preferred Stock During the quarter ended March 31, 2022, 3,657,730 3,657,730 Voting Rights Holders of Series A Preferred Stock (“Series A Holders”) have the right to receive notice of any meeting of holders of common stock and to vote upon any matter submitted to a vote of the holders of common stock. Each Series A Holder shall vote on each matter on an as converted basis submitted to them with the holders of common stock. Conversion Series A Preferred Stock converts to common stock at a 1:1 ratio immediately upon request of the Series A Holder Liquidation Series A Preferred Stock does not have preferential treatment over common stock shareholders if the Company liquidates or dissolves. Share-Based Compensation Plan The Company utilizes the Black-Scholes valuation method to recognize stock-based compensation expense over the vesting period. The expected life represents the period that the stock-based compensation awards are expected to be outstanding. Stock Option Activity On April 1, 2021, the Board of Directors of the Company approved and granted to certain directors and officers of the Company an aggregate of 54,750,000 4,750,000 0.07 The Board of Directors decided not to renew the former CEO’s (Robert Greif) employment contract; therefore, the unvested shares were forfeited resulting in a reduction of share-based compensation of approximately $ 205,000 At March 31, 2021, all outstanding stock options were fully vested, and related compensation expense recognized. At March 31, 2022, 29,635,000 options were outstanding and 18,218,333 were vested. For the three months ended March 31, 2022 and 2021, the Company recognized approximately $ 112,000 and $ 0 in stock-based compensation expense, respectively, which is included in share based compensation. At March 31, 2022, the Company has approximately $ 340,123 of unrecognized compensation costs related to non-vested stock options, which is expected to be recognized over a weighted average period of approximately 2.63 years. Inputs used in the valuation models are as follows: SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS 2021 Grants Option value $ 0.054 to $ 0.056 Risk Free Rate 0.90 % to 1.37 % Expected Dividend- yield - to - Expected Volatility 173.99 % to 176.04 % Expected term (years) 5 to 7 The following is a summary of stock option activity for the three months ended March 31, 2022 and 2021: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2020 410,000 $ 1.39 6.72 Granted - - - Expired/Cancelled - - - Outstanding and exercisable at March 31, 2021 410,000 $ 1.39 6.48 Outstanding at December 31, 2021 29,635,000 0.09 9.20 Granted - - - Outstanding at March 31, 2022 29,635,000 $ 0.09 8.96 Exercisable at March 31, 2022 18,218,333 $ 0.10 8.93 The following is a summary of the Company’s non-vested shares for the three months ended March 31, 2022: SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED Shares Weighted Non-vested at December 31, 2021 14,250,000 $ 0.06 Granted - - Vested (2,833,333 ) 0.05 Forfeited - - Non-vested at March 31, 2022 11,416,667 $ 0.07 Net Loss Per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock and if-converted methods, as applicable. Any potentially dilutive securities are antidilutive due to the Company’s net losses. The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE 2022 2021 For the Three Months Ended March 31, 2022 2021 Warrants to purchase common stock (in the money) 384,693,796 389,486,207 Series A Preferred Stock convertible to common stock 498,229,804 528,429,575 Total 882,923,600 917,915,782 Excluded from the above table are 2,196,355 warrants and 29,635,000 stock options for the three months ended March 31, 2022 and 23,937,765 410,000

COMMITMENTS & CONTINGENCIES

COMMITMENTS & CONTINGENCIES	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS & CONTINGENCIES	Note 6 – Commitments & Contingencies COMMITMENTS & CONTINGENCIES CEO Compensation Agreement On December 23, 2021, the Company entered into an employment agreement (the “Employment Agreement”) with Michael Yurkowsky, the Company’s Chief Executive Officer, to continue to serve as the Chief Executive Officer of the Company. Under the Employment Agreement, which commenced on December 1, 2021 (the “Effective Date”) and has a term of one year from the Effective Date (the “Employment Period”), Mr. Yurkowsky will receive a base salary of $ 180,000 In addition to his base salary, Mr. Yurkowsky may receive an one-time cash bonus in gross amount equal to $ 100,000 10,000,000 As additional compensation, Mr. Yurkowsky shall receive shares of common stock of the Company representing 1% of the Company’s fully diluted equity as of the grant date if the Company achieves a market capitalization of at least $ 250 500 The Equity Award was measured at fair value on its grant date using a Monte Carlo simulation model. The Monte Carlo simulation model includes assumptions for the expected term, volatility, and dividend yield, each of which are determined in reference to the Company’s historical results. The Company will recognize aggregate stock-based compensation expense of approximately $ 328,000 0.71 114,000 Consulting Agreements The Company entered into a consulting agreement with Tanya Rhodes of Rhodes & Associates, Inc, effective June 15, 2020, to serve as the Chief Science Officer of the Company. The agreement has a minimum term of six months with an average fee of $ 21,000 5 22,500 The Company entered into a consulting agreement with Alpha IR Group on March 1, 2022, to provide investor relations to the Company. The agreement is for twelve months with an average service fee of $ 9,750 Litigation From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect the Company’s financial condition, results of operations, and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention, and other factors. The Company expenses legal costs in the period incurred. The Company cannot assure that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against the Company in the future, and these matters could relate to prior, current or future transactions or events. The Company is involved in a lawsuit with Sinclair Broadcast Group, Inc. (“Sinclair”) which was filed on September 8, 2020, in the Circuit Court for the Thirteenth Judicial Circuit in and for Hillsborough County, Florida. Sinclair has filed suit alleging breach of contract for advertising services in the amount of approximately $ 75,000 The Company is involved in a lawsuit with ITN Networks, LLC (“ITN”) which was filed on July 22, 2021, in the Circuit Court for the Thirteenth Judicial Circuit in and for Hillsborough County, Florida. ITN has filed suit alleging breach of contract for advertising services in the amount of approximately $ 75,000 Guarantee The Company has guaranteed payments based upon the terms found in the management services agreements to affiliated physicians related to LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale. For the three months ended March 31, 2022 and 2021, payments totalling approximately $ 14,000 and $ 17,000 , respectively, were made to these physicians’ legal entities. Due to the Company ceasing operations effective March 23, 2020 in LI Dallas, LI Pittsburgh, and LI Scottsdale, in response to COVID-19, the guaranteed payments for these clinics were suspended in March 2020. The Company resumed these guaranteed payments in January 2021.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
DEBT	Note 7 – Debt DEBT Notes Payable Notes payable were assumed in the Merger (for further discussion, see Note 1 - “Overview” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K) and are due in aggregate monthly installments of approximately $ 5,800 and carry an interest rate of 5 %. Each note originally had a maturity date of August 1, 2019 . The Company finalized an eighteen-month extension to March 1, 2021. The promissory notes have an aggregate outstanding balance of approximately $ 69,000 at March 31, 2022 and December 31, 2021. The Company has not made payments on these notes since February 10, 2020, due to COVID-19. On April 19, 2022, the Company entered into a promissory note modification agreement with the Lender extending the maturity date of the notes to April 1, 2024 . The modification agreement also reduces the interest rate from 5 % to 3 % and requires a monthly payment of $ 1,000 per month with a balloon payment at the end of the modified term. Paycheck Protection Program On April 29, 2020, the Company issued a promissory note in the principal amount of $ 809,082 1 The Company could apply for loan forgiveness in an amount equal to the sum of the following costs incurred by the Company: 1) payroll costs; 2) any payment of interest on covered mortgage obligations; 3) any payment on a covered rent obligation; and 4) any covered utility payment The Company received notification from the Small Business Administration (“SBA”), dated August 17, 2021, notifying it that $ 689,974 in principal and $ 8,847 in interest was forgiven under the guidelines of the Paycheck Protection Program. As of March 31, 2022, the current balance is $ 26,536 with $ 33

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS	3 Months Ended
	Mar. 31, 2022
Common Stock Warrants
COMMON STOCK WARRANTS	Note 8 - Common Stock Warrants COMMON STOCK WARRANTS A summary of the Company’s warrant issuance activity and related information for the three months ended March 31, 2022 and 2021 is as follows: SCHEDULE OF ISSUANCE OF WARRANTS Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding and exercisable at December 31, 2020 413,423,972 $ 0.02 10.30 Expired - - - Exercised - - - Outstanding and exercisable at March 31, 2021 413,423,972 $ 0.10 9.24 Outstanding at December 31, 2021 406,301,497 0.04 8.17 Expired (20,411,346 ) 0.33 - Exercised (83,579,296 ) 0.01 - Granted 84,579,296 0.01 4.88 Outstanding and exercisable at March 31, 2022 386,890,151 $ 0.02 7.57 The fair value of all warrants issued are determined by using the Black-Scholes valuation technique. The inputs used in the Black-Scholes valuation technique to value each of the warrants as of their respective issue dates are as follows: SCHEDULE OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Granted for inducement agreement 1/19/2022 3,732,289 $ 0.06 $ 0.014 $ 0.062 5 1.62 187.79 Granted for inducement agreement 1/20/2022 372,289 $ 0.07 $ 0.014 $ 0.064 5 1.62 187.85 Granted for inducement agreement 1/20/2022 187,201 $ 0.07 $ 0.014 $ 0.064 5 1.62 187.85 Granted for inducement agreement 1/24/2022 374,403 $ 0.05 $ 0.014 $ 0.047 5 1.53 188.01 Granted for inducement agreement 1/25/2022 3,744,031 $ 0.05 $ 0.014 $ 0.048 5 1.56 188.00 Granted for inducement agreement 2/02/2022 3,740,509 $ 0.05 $ 0.014 $ 0.044 5 1.60 188.25 Granted for inducement agreement 2/04/2022 6,934,785 $ 0.04 $ 0.014 $ 0.043 5 1.78 188.33 Granted for inducement agreement 2/04/2022 13,869,643 $ 0.04 $ 0.014 $ 0.043 5 1.78 188.33 Granted for services provided 2/09/2022 1,000,000 $ 0.03 $ 0.014 $ 0.031 5 1.82 188.69 Granted for inducement agreement 2/22/2022 41,608,884 $ 0.03 $ 0.014 $ 0.032 5 1.85 188.59 Granted for inducement agreement 2/22/2022 693,477 $ 0.03 $ 0.014 $ 0.032 5 1.85 188.59 Granted for inducement agreement 3/21/2022 8,321,785 $ 0.03 $ 0.014 $ 0.027 5 2.33 194.01 The fair value of warrants issued during the three months ended March 31, 2022 totaled approximately $ 3,000,000 The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	N ote 9 - Subsequent Events SUBSEQUENT EVENTS As of May 3, 2022, an additional 3,650,685 Series A Preferred Stock was converted into Common Stock at the request of certain Series A Preferred Stockholders.

EQUITY TRANSACTIONS (Tables)

EQUITY TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS	Inputs used in the valuation models are as follows: SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS 2021 Grants Option value $ 0.054 to $ 0.056 Risk Free Rate 0.90 % to 1.37 % Expected Dividend- yield - to - Expected Volatility 173.99 % to 176.04 % Expected term (years) 5 to 7
SUMMARY OF STOCK OPTION ACTIVITY	The following is a summary of stock option activity for the three months ended March 31, 2022 and 2021: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2020 410,000 $ 1.39 6.72 Granted - - - Expired/Cancelled - - - Outstanding and exercisable at March 31, 2021 410,000 $ 1.39 6.48 Outstanding at December 31, 2021 29,635,000 0.09 9.20 Granted - - - Outstanding at March 31, 2022 29,635,000 $ 0.09 8.96 Exercisable at March 31, 2022 18,218,333 $ 0.10 8.93
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED	The following is a summary of the Company’s non-vested shares for the three months ended March 31, 2022: SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED Shares Weighted Non-vested at December 31, 2021 14,250,000 $ 0.06 Granted - - Vested (2,833,333 ) 0.05 Forfeited - - Non-vested at March 31, 2022 11,416,667 $ 0.07
SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE	The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE 2022 2021 For the Three Months Ended March 31, 2022 2021 Warrants to purchase common stock (in the money) 384,693,796 389,486,207 Series A Preferred Stock convertible to common stock 498,229,804 528,429,575 Total 882,923,600 917,915,782

COMMON STOCK WARRANTS (Tables)

COMMON STOCK WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2022
Common Stock Warrants
SCHEDULE OF ISSUANCE OF WARRANTS	A summary of the Company’s warrant issuance activity and related information for the three months ended March 31, 2022 and 2021 is as follows: SCHEDULE OF ISSUANCE OF WARRANTS Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding and exercisable at December 31, 2020 413,423,972 $ 0.02 10.30 Expired - - - Exercised - - - Outstanding and exercisable at March 31, 2021 413,423,972 $ 0.10 9.24 Outstanding at December 31, 2021 406,301,497 0.04 8.17 Expired (20,411,346 ) 0.33 - Exercised (83,579,296 ) 0.01 - Granted 84,579,296 0.01 4.88 Outstanding and exercisable at March 31, 2022 386,890,151 $ 0.02 7.57
SCHEDULE OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE	SCHEDULE OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Granted for inducement agreement 1/19/2022 3,732,289 $ 0.06 $ 0.014 $ 0.062 5 1.62 187.79 Granted for inducement agreement 1/20/2022 372,289 $ 0.07 $ 0.014 $ 0.064 5 1.62 187.85 Granted for inducement agreement 1/20/2022 187,201 $ 0.07 $ 0.014 $ 0.064 5 1.62 187.85 Granted for inducement agreement 1/24/2022 374,403 $ 0.05 $ 0.014 $ 0.047 5 1.53 188.01 Granted for inducement agreement 1/25/2022 3,744,031 $ 0.05 $ 0.014 $ 0.048 5 1.56 188.00 Granted for inducement agreement 2/02/2022 3,740,509 $ 0.05 $ 0.014 $ 0.044 5 1.60 188.25 Granted for inducement agreement 2/04/2022 6,934,785 $ 0.04 $ 0.014 $ 0.043 5 1.78 188.33 Granted for inducement agreement 2/04/2022 13,869,643 $ 0.04 $ 0.014 $ 0.043 5 1.78 188.33 Granted for services provided 2/09/2022 1,000,000 $ 0.03 $ 0.014 $ 0.031 5 1.82 188.69 Granted for inducement agreement 2/22/2022 41,608,884 $ 0.03 $ 0.014 $ 0.032 5 1.85 188.59 Granted for inducement agreement 2/22/2022 693,477 $ 0.03 $ 0.014 $ 0.032 5 1.85 188.59 Granted for inducement agreement 3/21/2022 8,321,785 $ 0.03 $ 0.014 $ 0.027 5 2.33 194.01

LIQUIDITY, GOING CONCERN AND _2

LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Apr. 29, 2022	Jan. 31, 2022
Subsequent Event [Line Items]
Net loss	$ 3,891,783	$ 1,407,674
Cash and Cash Equivalents, at Carrying Value	341,000
Proceeds from warrant exercises	$ 1,170,110
Warrant Holders [Member]
Subsequent Event [Line Items]
Exercise price of warrant	$ 0.014			$ 0.014
Warrant term	5 years			5 years
Exercise on aggregate of warrants	83,579,296
Proceeds from warrant exercises	$ 1,170,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Cash and Cash Equivalents, at Carrying Value			$ 92,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Jan. 17, 2022	Jan. 02, 2022	Oct. 14, 2021	Apr. 01, 2021	Mar. 01, 2021	Jan. 12, 2021	Jan. 02, 2021	Oct. 01, 2020	Mar. 31, 2022	Mar. 31, 2021
Professional fees							$ 22,500
Secured Convertible Note Purchase Agreement [Member]
Debt instrument, face amount				$ 2,575,000
Debt instrument, maturity date				Mar. 31, 2022
Debt instrument, interest rate				8.00%
Secured Convertible Note Purchase Agreement [Member] | Common Stock [Member]
Debt instrument, discount rate				20.00%
Second Closing Bring Down Agreement [Member]
Debt instrument, face amount			$ 750,000
Debt instrument, maturity date			Mar. 31, 2022
Debt instrument, interest rate			8.00%
Debt instrument, discount rate			20.00%
Raymond Monteleone [Member]
Professional fees		$ 7,500				$ 5,000
Additional fees		$ 2,500				2,500
Officers compensation									$ 25,000	$ 17,500
Michael Yurkowsky [Member] | Oral Agreement [Member]
Professional fees								$ 4,167
Officers compensation									0	12,500
William Horne [Member] | Oral Agreement [Member]
Professional fees					$ 4,167	5,000
Officers compensation									20,000	4,000
Deferred salary and compensation						$ 108,000
Richard Rosenblum [Member] | Oral Agreement [Member]
Professional fees	$ 5,000
Officers compensation									12,500	$ 0
Matthew Anderer [Member] | Oral Agreement [Member]
Professional fees	$ 5,000
Officers compensation									$ 12,500
Investor [Member] | Secured Convertible Note Purchase Agreement [Member] | FWHC Bridge, LLC [Member]
Proceeds from convertible debt				$ 1,500,000
Investor [Member] | Secured Convertible Note Purchase Agreement [Member] | FWHC [Member]
Proceeds from convertible debt				$ 25,000
Investor [Member] | Second Closing Bring Down Agreement [Member] | FWHC Bridge, LLC [Member]
Proceeds from convertible debt			$ 437,000
Investor [Member] | October 2021 Note Purchase Agreement [Member] | FWHC Bridge, LLC [Member]
Proceeds from convertible debt			$ 7,000

SCHEDULE OF ASSUMPTIONS USED TO

SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS (Details) - 2021 Grants [Member]	3 Months Ended
	Mar. 31, 2022$ / shares
Minimum [Member]
Option value	$ 0.054
Risk Free Rate	0.90%
Expected Dividend- yield
Expected Volatility	173.99%
Expected term (years)	5 years
Maximum [Member]
Option value	$ 0.056
Risk Free Rate	1.37%
Expected Dividend- yield
Expected Volatility	176.04%
Expected term (years)	7 years

SUMMARY OF STOCK OPTION ACTIVIT

SUMMARY OF STOCK OPTION ACTIVITY (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Equity [Abstract]
Shares, outstanding beginning balance	29,635,000	410,000
Weighted average exercise price, outstanding beginning balance	$ 0.09	$ 1.39
Weighted average remaining, term outstanding	9 years 2 months 12 days	6 years 8 months 19 days
Shares, granted
Weighted average exercise price, granted
Shares, expired cancelled
Weighted average exercise price, expired / cancelled
Shares outstanding, ending balance	29,635,000	410,000
Shares exercise price outstanding, ending balance	$ 0.09	$ 1.39
Shares remaining term outstanding, ending balance	8 years 11 months 15 days	6 years 5 months 23 days
Shares Exercisable, ending balance	18,218,333
Shares exercise price exercisable ending balance	$ 0.10
Weighted average remaining term (Years), exercisable	8 years 11 months 4 days

SUMMARY OF STOCK OPTION ACTIV_2

SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Equity [Abstract]
Non-vested shares outstanding, beginning balance | shares	14,250,000
Non-vested, weighted average grant date fair value, outstanding beginning balance | $ / shares	$ 0.06
Non-vested shares, granted | shares
Non-vested, weighted average grant date fair value, granted | $ / shares
Non-vested shares, vested | shares	(2,833,333)
Non-vested, weighted average grant date fair value, vested | $ / shares	$ 0.05
Non-vested shares, forfeited | shares
Non-vested, weighted average grant date fair value, forfeited | $ / shares
Non-vested shares outstanding, ending balance | shares	11,416,667
Non-vested, weighted average grant date fair value, outstanding ending balance | $ / shares	$ 0.07

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	882,923,600	917,915,782
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	384,693,796	389,486,207
Series A Preferred Stock Convertible to Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	498,229,804	528,429,575

EQUITY TRANSACTIONS (Details Na

EQUITY TRANSACTIONS (Details Narrative) - USD ($)	Apr. 01, 2021	Mar. 31, 2022	Mar. 31, 2021	Sep. 30, 2021	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Proceeds from warrant exercises		$ 1,170,110
Share based compensation, stock option granted
Share based compensation, stock option vested		2,833,333
Share based compensation, stock option exercise price
Share-based payment arrangement		$ 226,079
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number		29,635,000	410,000			29,635,000	410,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 340,123
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		9 years 2 months 12 days	6 years 8 months 19 days
Anti-dilutive securities		882,923,600	917,915,782
Warrants [Member]
Class of Stock [Line Items]
Anti-dilutive securities		2,196,355	23,937,765
Stock Options [Member]
Class of Stock [Line Items]
Anti-dilutive securities		29,635,000	410,000
Share-Based Payment Arrangement [Member]
Class of Stock [Line Items]
Share based compensation, stock option vested		18,218,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number		29,635,000
Share-Based Payment Arrangement, Expense		$ 112,000	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		2 years 7 months 17 days
Common Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares		3,657,730
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares		3,657,730
Preferred stock, voting rights		Holders of Series A Preferred Stock (“Series A Holders”) have the right to receive notice of any meeting of holders of common stock and to vote upon any matter submitted to a vote of the holders of common stock. Each Series A Holder shall vote on each matter on an as converted basis submitted to them with the holders of common stock.
Conversion of stock, description		converts to common stock at a 1:1 ratio immediately upon request of the Series A Holder
Warrant Holders [Member]
Class of Stock [Line Items]
Exercise price of warrant		$ 0.014			$ 0.014
Warrant term		5 years			5 years
Exercise on aggregate of warrants		83,579,296
Proceeds from warrant exercises		$ 1,170,000
Directors and Officers [Member]
Class of Stock [Line Items]
Share based compensation, stock option granted	54,750,000
Share based compensation, stock option vested	4,750,000
Share based compensation, stock option exercise price	$ 0.07
Chief Executive Officer [Member]
Class of Stock [Line Items]
Share-based payment arrangement				$ 205,000

COMMITMENTS & CONTINGENCIES (De

COMMITMENTS & CONTINGENCIES (Details Narrative) - USD ($)	Mar. 02, 2022	Dec. 23, 2021	Jan. 02, 2021	Jun. 15, 2020	Mar. 31, 2022	Mar. 31, 2021
Loss Contingencies [Line Items]
Employment bonus					$ 347,219	$ 661,775
Share-Based Compensation Arrangement by Share-Based Payment Award, Description		As additional compensation, Mr. Yurkowsky shall receive shares of common stock of the Company representing 1% of the Company’s fully diluted equity as of the grant date if the Company achieves a market capitalization of at least $250 million for 60 consecutive days during the Employment Period (the “Equity Award”). If the Company achieves a market capitalization of at least $500 million for 60 consecutive days during the Employment Period, the executive shall receive an additional Equity Award of 1%, such that he has in the aggregate received shares of common stock of the Company representing 2% of the Company’s fully diluted equity as of the date of grant.
Equity award based compensation expense					114,000
Professional fees			$ 22,500
Guarantor Obligations, Current Carrying Value					14,000	$ 17,000
Sinclair Broadcast Group Inc [Member]
Loss Contingencies [Line Items]
Advertising Expense					75,000
ITN Network LLC [Member]
Loss Contingencies [Line Items]
Advertising Expense					$ 75,000
Employment Agreement [Member] | Chief Executive Officer [Member] | Yurkowsky [Member]
Loss Contingencies [Line Items]
Base salary		$ 180,000
Employment bonus		100,000
Secures and financing receivable		10,000,000
Equity Award [Member]
Loss Contingencies [Line Items]
Share based compensation expense		$ 328,000
Straight line basis derived service period		8 months 15 days
Equity Award [Member] | Chief Executive Officer [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Employee Benefits and Share-Based Compensation		$ 250,000,000
Equity Award [Member] | Chief Executive Officer [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Employee Benefits and Share-Based Compensation		$ 500,000,000
Consulting Agreement [Member] | Tanya Rhodes of Rhodes and Associates Inc [Member]
Loss Contingencies [Line Items]
Professional average fee				$ 21,000
Increase in professional average fee percentage				5.00%
Consulting Agreement [Member] | Aplha IR Group [Member]
Loss Contingencies [Line Items]
Professional average fee	$ 9,750

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)	Apr. 19, 2022	Aug. 17, 2021	Mar. 31, 2022	Dec. 31, 2021	Apr. 29, 2020
Paycheck Protection Program [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate					1.00%
Debt principal amount		$ 689,974			$ 809,082
Interest Expense, Debt		$ 8,847
Debt Instrument, Periodic Payment, Principal			$ 26,536
Interest payable			33
Notes Payable [Member]
Short-Term Debt [Line Items]
Debt Instrument, Periodic Payment			$ 5,800
Debt instrument interest rate			5.00%
Debt Instrument, Maturity Date			Aug. 1, 2019
Notes Payable [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Debt Instrument, Periodic Payment	$ 1,000
Debt Instrument, Maturity Date	Apr. 1, 2024
Notes Payable [Member] | Subsequent Event [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate	5.00%
Notes Payable [Member] | Subsequent Event [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate	3.00%
Promissory Note [Member]
Short-Term Debt [Line Items]
Notes Payable			$ 69,000	$ 69,000

SCHEDULE OF ISSUANCE OF WARRANT

SCHEDULE OF ISSUANCE OF WARRANTS (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Common Stock Warrants
Number of Shares, Warrants Outstanding and Exercisable, Beginning	406,301,497	413,423,972
Weighted Average Exercise Price Outstanding and Exercisable, Beginning	$ 0.04	$ 0.02
Weighted Average Remaining Contractual Life Warrants Outstanding and Exercisable, Beginning	8 years 2 months 1 day	10 years 3 months 18 days
Number of Shares, Warrants Outstanding and Expired	(20,411,346)
Weighted Average Exercise Price Warrants	$ 0.33
Number of Shares, Warrants Exercised	(83,579,296)
Weighted Average Exercise Price Warrants Exercised	$ 0.01
Number of Shares, Warrants Outstanding and Exercisable, Ending	386,890,151	413,423,972
Weighted Average Exercise Price Outstanding and Exercisable, Ending	$ 0.02	$ 0.10
Weighted Average Remaining Contractual Life Warrants Outstanding and Exercisable, Ending	7 years 6 months 25 days	9 years 2 months 26 days
Number of Shares, Warrants Granted	84,579,296
Weighted Average Exercise Price Warrants Granted	$ 0.01
Weighted Average Remaining Contractual Life Warrants Granted	4 years 10 months 17 days

SCHEDULE OF ISSUANCE OF WARRA_2

SCHEDULE OF ISSUANCE OF WARRANTS VALUATION TECHNIQUE (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Granted For Services Provided [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	1,000,000
Share Price	$ 0.03
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.031
Life of Warrant	5 years
Measurement Input, Risk Free Interest Rate [Member] | Granted For Services Provided [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.82
Measurement Input, Price Volatility [Member] | Granted For Services Provided [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	188.69
Granted For Inducement Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	3,732,289
Share Price	$ 0.06
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.062
Life of Warrant	5 years
Granted For Inducement Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.62
Granted For Inducement Agreement [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	187.79
Granted For Inducement Agreement One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	372,289
Share Price	$ 0.07
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.064
Life of Warrant	5 years
Granted For Inducement Agreement One [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.62
Granted For Inducement Agreement One [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	187.85
Granted For Inducement Agreement Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	187,201
Share Price	$ 0.07
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.064
Life of Warrant	5 years
Granted For Inducement Agreement Two [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.62
Granted For Inducement Agreement Two [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	187.85
Granted For Inducement Agreement Three [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	374,403
Share Price	$ 0.05
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.047
Life of Warrant	5 years
Granted For Inducement Agreement Three [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.53
Granted For Inducement Agreement Three [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	188.01
Granted For Inducement Agreement Four [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	3,744,031
Share Price	$ 0.05
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.048
Life of Warrant	5 years
Granted For Inducement Agreement Four [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.56
Granted For Inducement Agreement Four [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	188
Granted For Inducement Agreement Five [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	3,740,509
Share Price	$ 0.05
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.044
Life of Warrant	5 years
Granted For Inducement Agreement Five [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.60
Granted For Inducement Agreement Five [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	188.25
Granted For Inducement Agreement Six [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	6,934,785
Share Price	$ 0.04
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.043
Life of Warrant	5 years
Granted For Inducement Agreement Six [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.78
Granted For Inducement Agreement Six [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	188.33
Granted For Inducement Agreement Seven [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	13,869,643
Share Price	$ 0.04
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.043
Life of Warrant	5 years
Granted For Inducement Agreement Seven [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.78
Granted For Inducement Agreement Seven [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	188.33
Granted For Inducement Agreement Eight [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	41,608,884
Share Price	$ 0.03
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.032
Life of Warrant	5 years
Granted For Inducement Agreement Eight [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.85
Granted For Inducement Agreement Eight [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	188.59
Granted For Inducement Agreement Nine [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	693,477
Share Price	$ 0.03
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.032
Life of Warrant	5 years
Granted For Inducement Agreement Nine [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	1.85
Granted For Inducement Agreement Nine [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	188.59
Granted For Inducement Agreement Ten [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	8,321,785
Share Price	$ 0.03
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.014
Warrant Grant Date Fair Value	$ 0.027
Life of Warrant	5 years
Granted For Inducement Agreement Ten [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	2.33
Granted For Inducement Agreement Ten [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant Input, Percentage	194.01

COMMON STOCK WARRANTS (Details

COMMON STOCK WARRANTS (Details Narrative)	3 Months Ended
	Mar. 31, 2022USD ($)
Warrant Issued [Member]
Interest expense	$ 3,000,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	May 03, 2022shares
Subsequent Event [Member] | Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	3,650,685